Vertex Pharmaceuticals (1VRTX) Stock Price & Analysis
1VRTX Stock Chart & Stats
- Day’s Range
- EUR 494.10 - EUR 494.10
- 52-Week Range
- EUR 316.00 - EUR 609.00
- Previous Close
- EUR 484.20
- Volume
- 1
- Average Volume (3M)
- 6
- Market Cap
- EUR 126.84B
- Enterprise Value
- EUR 120.88B
- Total Cash (Recent Filing)
- EUR 7.85B
- Total Debt (Recent Filing)
- EUR 1.98B
- Price to Earnings (P/E)
- 32.3
- Beta
- 0.06
- Next Earnings
- Nov 02, 2026 (Est.)
- EPS Estimate
- 4.31
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Profitability
Vertex combines substantial revenue with exceptionally high gross and operating margins, demonstrating strong economics in its established business. This profitability provides resources to fund research, commercial expansion, and strategic opportunities while preserving resilience if individual programs or markets fluctuate.
Strong Cash Generation
Robust operating and free cash flow indicate that reported earnings are converting effectively into financial resources. This supports sustained internal investment, capital returns, and the ability to pursue growth without relying heavily on external financing under normal operating conditions.
Commercial And Pipeline Breadth
Vertex is extending growth beyond its established CF franchise through multiple commercial launches and advancing clinical programs. Progress across pain, renal disease, cell therapy, and diabetes creates additional potential growth pillars and reduces reliance on a single future product outcome.
Bears Say
Expense And Margin Pressure
Elevated commercial spending and manufacturing investment are absorbing part of the benefit from revenue growth, while management expects operating expenses near the top of its range. If these investments take longer to mature, margin expansion and earnings growth could remain constrained.
Acquisition Leverage Risk
The Crinetics transaction adds meaningful debt and integration obligations before expected operating-income accretion arrives. That timing can reduce near-term financial flexibility and raises execution requirements, especially if the acquired portfolio takes longer than planned to contribute.
Access And Conversion Gaps
Incomplete and restricted payer coverage may limit how efficiently strong prescription growth converts into durable net revenue. Expanding access and overcoming prior authorization or quantity limits will remain important to sustaining the product's commercial trajectory.
Vertex Pharmaceuticals News
1VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
What is Vertex Pharmaceuticals’s market cap?
When is Vertex Pharmaceuticals’s upcoming earnings report date?
How were Vertex Pharmaceuticals’s earnings last quarter?
Is Vertex Pharmaceuticals overvalued?
Does Vertex Pharmaceuticals pay dividends?
What is Vertex Pharmaceuticals’s EPS estimate?
How many shares outstanding does Vertex Pharmaceuticals have?
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Vertex Pharmaceuticals Stock Smart Score
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani
- Employees
- 6,400
- Website
- www.vrtx.com
- Address
- 50 Northern Avenue, Boston, MA, 02210, US
Vertex Pharmaceuticals (1VRTX) Earnings & Revenues
1VRTX Company Deck
1VRTX Earnings Call
Earnings Call SentimentPositive
The call presented a largely positive commercial and clinical update: revenue and key product launches (ALYFTREK, CASGEVY, JOURNAVX) showed strong momentum, guidance was raised, multiple clinical and regulatory milestones were achieved or on track (Pove BLA accepted, AMPLITUDE/AMPLIFIED/AGLOW enrollment complete or progressing, VX‑017 IND cleared), and the Crinetics acquisition adds a new specialty pillar. Offsetting factors include higher SG&A and upcoming operating expense at the high end of guidance, gross margin pressure from product mix and manufacturing investments, short‑term revenue volatility for cell therapies and PSP‑driven gross‑to‑net impacts (normalization expected in H1 2027), and near‑term costs and debt associated with the Crinetics deal. Overall, the positive commercial execution and pipeline progress outweigh the near‑term cost and execution risks.
View all IT:1VRTX earnings summaries1VRTX Net sales Breakdown
- 85.93% TRIKAFTA/KAFTRIO
- 6.98% ALYFTREK
- 6.83% Other product revenues
- 0.26% Other revenues
1VRTX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 5 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |
